Literature DB >> 820733

Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations.

A Szczeklik, R J Gryglewski, G Czerniawska-Mysik, A Zmuda.   

Abstract

Eighteen patients with asthma and aspirin hypersensitivity have been challenged with increasing doses of aspirin, fenoprofen, ibuprofen, and dextropropoxyphene. Low doses of the first three drugs induced bronchoconstriction in all the patients as evidenced by fall in peak expiratory flow and appearance of clinical symptoms. There were no reactions to therapeutic doses of dextropropoxyphene. Aspirin, fenoprofen, and ibuprofen, but not dextropropoxyphene, inhibited prostaglandin synthetase activity in three different microsomal preparations, i.e., in bovine seminal vesicles, in rabbit brain, and in rabbit kidney medulla. Expected in vivo antienzymic potency of a drug, calculated from experiments using rabbit brain microsomes, corresponded roughly with its potency to induce bronchoconstriction in the challenge tests. An individual pattern of sensitivity to threshold doses of prostaglandin synthetase inhibitors was demonstrated for each patient. The results obtained suggest that precipitation of asthmatic attacks by nonsteroidal anti-inflammatory drugs is mediated through inhibition of prostaglandin biosynthesis. The degree of enzymic inhibition, which is sufficient to precipitate bronchoconstriction, is an individual hallmark. Knowing the threshold dose for any of prostaglandin synthetase inhibitors in a patient, one can predict the threshold doses for the rest of aspirin-like drugs in this particular patient.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820733     DOI: 10.1016/0091-6749(76)90102-0

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  15 in total

Review 1.  The use of analgesics in patients with asthma.

Authors:  S Levy; G Volans
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma.

Authors:  A Szczeklik; R J Gryglewski; G Czerniawska-Mysik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

3.  Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.

Authors:  Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty
Journal:  J Allergy Clin Immunol       Date:  2017-03-06       Impact factor: 10.793

4.  Asthma and anti-inflammatory drugs. Mechanisms and clinical patterns.

Authors:  A Szczeklik; R J Gryglewski
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

5.  Sensitivity to tartrazine.

Authors:  K Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1982-12-04

Review 6.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 7.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

8.  Production of PGE2 by bovine cultured airway smooth muscle cells and its inhibition by cyclo-oxygenase inhibitors.

Authors:  F Delamere; E Holland; S Patel; J Bennett; I Pavord; A Knox
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 9.  Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice.

Authors:  Christine Jenkins; John Costello; Linda Hodge
Journal:  BMJ       Date:  2004-02-21

10.  Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.

Authors:  Tao Liu; Tanya M Laidlaw; Howard R Katz; Joshua A Boyce
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.